Fabry's Disease: A Case series report of a Libyan family
DOI:
https://doi.org/10.54361/ljmr.16211Keywords:
Fabry's Disease, a-galactosidase, chronic kidney disease, Enzyme Replacement TherapyAbstract
Introduction Fabry's disease (FD) is a rare disorder due to the very low residual function of alpha galactosidase enzyme causing chronic kidney disease (CKD), with the incidence of 1/40,000 males. Heterozygous females may be asymptomatic. We hereby report a patient having CKD and other clinical findings like, dermatological, neurological and cardiological manifestations and pedigree analysis were strongly suggest the diagnosis of Fabry Disease. Case Presentation: A 40-year-old man with high renal profile the patient is normotensive, non-diabetic, in 2013 had history of left ophthalmoplegia which resulted from acute ischemia in midbrain, in 2014 had bilateral sensory neural hearing loss. In 2019 was noticed that he had a skin rash in a “bathing-trunk” distribution, they are small angiomas, by physical examination patient looks pale, he has mild pedal edema, CNS examination showed 7th, 8th and 9th cranial nerve palsy, his investigations showed raised s. creatinine 3.2 mg/dl, Urine protein++, eGFR 22.4/min/1.73m2. Ultrasound abdomen showed small kidneys and echocardiography showed LVH. A pedigree analysis showed recipient was third in birth order and has two brothers a known case of CKD on regular hemodialysis, The CKD of the brothers was a result of Fabry Disease, was evaluated for a-galactosidase activity which was found markedly decreased (12.10; normal enzyme activity level >60). According to clinical manifestations and strong family history of FD, Conclusion & Recommendations: This case report highlights the importance of careful evaluation of cases of CKD due to unusual causes, particularly when there's positive family history, in order to avoid misdiagnosis and also for early and proper therapy.
References
McGovern MM, Desnick RJ. Lysosomal storage diseases. Cecil Textbook of Medicine. In: Goldman L, editor. 21st ed. St. Louis: W.B. Saunders Company; 2000. pp. 1104–7.
Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, etal. Patients with Fabrydisease on dialysis in the United States. Kidney Int. 2002; 61:249–55. DOI: https://doi.org/10.1046/j.1523-1755.2002.00097.x
Brady RO, Grabowski GA, Thadhani R. United states: Gardiner-Caldwell Syner Med; 2001. Fabry Disease: Review and New Perspectives; pp. 1– 8.
Ojo A, Meier-Kriesche HU, Friedman G, Hanson J, Cibrik D, Leichtman A, et al. Excellent outcome of renal transplantation in patients with Fabry's disease. eISSN:2413-6096 http://www.ljmr.com.ly/Transplantation.2000;69:2337– 9. DOI: https://doi.org/10.1097/00007890-200006150-00020
Obrador GT, Ojo A, Thadhani R. End-stage renal disease in patients with Fabry disease. J AmSocNephrol.2002;13(Suppl1): S144–6. DOI: https://doi.org/10.1097/01.ASN.0000015237.87719.DC
Tsakiris D, Simpson HK, Jones EH, Briggs JD, Elinder CG, Mendel S, et al. Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant. 1996;11(Suppl 1):4– 20. DOI: https://doi.org/10.1093/ndt/11.supp7.4
Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and fabry nephropathy: Sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. JAm SocNephrol.2007;18:2609–17. DOI: https://doi.org/10.1681/ASN.2006121400
Alroy J, Sabnis S, Kopp JB. Nanopathology yin Fabry disease. Jam Soc Nephr ol.
2002;13(Suppl1): S134–8.
Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural history of Fabry renal disease: Influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81: 122–38 DOI: https://doi.org/10.1097/00005792-200203000-00003
Batista EC, Carvalho LR, Casarini DE, Carmona AK, dos Santos EL, da Silva ED, et al. ACE activity is modulated by the enzyme a-galactosidase A. J Mol Med (Berl) 2011;89:65– 74 DOI: https://doi.org/10.1007/s00109-010-0686-2
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney Int Suppl. 2009;76: S1– 130
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Ali A. Alahrash, Roudaba Betro (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.